PROCEPT BioRobotics stock jumped 5.8% to US$19.34 after its Q2 earnings, even though the broader three month stretch for the shares has been weak. The move reflects a simple story. Investors are rewarding evidence that the growth engine is still firing while withholding any credit for profits that are not yet there.

The headline this quarter is revenue. PROCEPT BioRobotics reported US$94.5m in Q2 sales and management kept full year revenue guidance of US$390m to US$410m intact. That confidence landed alongside a net loss of US$26.9m, which keeps the spotlight firmly on how long the market will keep paying up for growth over earnings.

Is PROCEPT BioRobotics stock pricing in sensible growth, or are investors paying up despite a wide gap to the provided cash flow value estimate? Compare the current setup against our valuation analysis for PROCEPT BioRobotics.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$94.5m vs. US$79.2m (higher year on year)
• Net Loss, Q2 2026 vs. Q2 2025: US$26.9m loss vs. US$19.6m loss (loss widened)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.47 loss per share vs. US$0.35 loss per share (loss per share increased)
• Gross Margin, Q2 2026: 66% in Q2 2026, supported by a US$2.9m tariff recovery

Prefer clear charts instead of another page of numbers and jargon? See PROCEPT BioRobotics’ full financial picture with a visual breakdown of its valuation and key drivers in our company report for PROCEPT BioRobotics.

Evaluating Whether PROCEPT’s Growth Story Is Holding Up

Bulls argue that PROCEPT BioRobotics can keep expanding through wider adoption, stronger reimbursement support and execution on HYDROS system rollouts. Q2 offers mixed but important progress markers. U.S. procedures rose to more than 13,100, and management kept full year revenue guidance intact, which suggests underlying demand remains supportive even after the discounting controversy earlier in 2026. HYDROS looks central to the bullish case. PROCEPT sold 65 HYDROS systems in the quarter with a record U.S. average selling price near US$495,000 and a faster utilization ramp than legacy AQUABEAM sites. That directly supports the idea that the upgraded platform can drive higher long term handpiece pull through.

On the financial runway claim, PROCEPT ended Q2 with about US$231m in cash and still targets roughly 65% gross margin for 2026, although current losses remain significant. That combination gives room to keep funding trials and commercial expansion that the growth thesis relies on.

Compare that operational momentum at PROCEPT BioRobotics with how the street is recalibrating expectations. See the consensus price target analysis for PROCEPT BioRobotics to check whether analysts think the recent progress justifies the current share price.

PROCEPT Bear Case: Execution Wobbles Keep Risk Front and Center

The harshest bears argue that PROCEPT BioRobotics sits on shaky execution, pressured reimbursement and fragile demand once discounting is stripped out. Q2 does not fully clear that bar. Management hit the revenue guide but openly conceded that procedure growth “fell short of internal expectations” and that the weakness was concentrated in legacy AQUABEAM accounts. That is a miss against the idea of a smooth, broad based adoption curve.

Reimbursement and economics also remain a live concern. Physicians are digesting prior reimbursement cuts and PROCEPT is now spending more on commercial efforts, with 2026 operating expense guidance nudged higher and the net loss at US$26.9m. The 66% gross margin relied on a one off US$2.9m tariff recovery, which is not a structural fix for supply chain or China related tariff risk. The company still needs clearer proof that utilization and profitability can stand without temporary boosts.

Review whether PROCEPT’s widening losses and tariff dependent margin are isolated issues or part of a broader risk pattern when you scan our risk analysis for PROCEPT BioRobotics which shows 1 important warning sign.

Take Control Of Your Next Move

If PROCEPT BioRobotics’ mix of strong revenue guidance, widening losses and tariff sensitive margins has your attention, register for FREE with Simply Wall St and add it to a Watchlist to track share price against fair value and watch how the story develops. Once you decide to take a position, keep your decisions sharp by managing your holdings through the Portfolio Command Center that focuses you on key fundamental and valuation alerts instead of day to day noise. For a broader view on what other investors are seeing in PROCEPT BioRobotics and similar stocks, tap into the Community and compare real time perspectives and theses. Spot potential catalysts or emerging risks early and stay a step ahead of the market.

Seeking Alternatives Beyond PROCEPT BioRobotics

Fresh ideas can move quickly. New themes gather momentum, early entries fly, and late arrivals get caught chasing. Scan curated stock shortlists while it matters and get in early.

• Spot companies with strong cash backing and sturdy fundamentals, then compare them side by side using the curated list of solid balance sheet and fundamentals stocks (50 results) before the crowd fully catches on.
• Ride potential cash rich AI momentum while these opportunities are still under the radar for now by scanning the hand picked 67 profitable AI stocks that aren't just burning cash list and acting before sentiment turns.
• Position ahead of possible infrastructure build outs by reviewing curated 36 power grid technology and infrastructure stocks that could benefit if grid upgrades gain traction, and do it before prices start running.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.